Poor Sleep
Sanofi India Limited and Cipla Limited have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.
While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.
Doctors at AIIMS Delhi have successfully performed a rare and technically demanding lung-preserving surgery on…
Sharda Hospital successfully performed a rare scarless surgery to remove a massive benign facial tumor…
A 29-year-old woman with a severe post-burn deformity of the left chest and breast, resulting…
Zydus Lifesciences with Guardant Health, having an agreement to make the Shield™ Multi-Cancer Detection (MCD)…
In the backdrop of observation that India may emerge as the Cancer Capital of the…
The Centre has amended the Drugs rule, omitting the word “Syrup” from Schedule K, the…